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Hodgkin lymphoma (HL) is an immunologically active lymphoid neoplasm composed of a few (usually 
1-10%) neoplastic Hodgkin and Reed-Sternberg (HRS) cells or lymphocyte predominant (LP) cells and 
>90% non-neoplastic cells, mainly T- and B-lymphocytes, plasma cells, macrophages, eosinophils and 
fibroblasts. The substantial amount of reactive cells in HL is supposed to be the net effect of a 
complex network of cytokines and chemokines secreted by either the HRS cells or non-neoplastic 
cells (1). One component of this network is transforming growth factor beta (TGF-β), which is 
produced by HRS cells and cancer-associated fibroblasts. TGF-β unfolds its immunosuppressive 
impact by stimulating tumor-infiltrating T-lymphocytes (TIL) to differentiate into anergic, tumor-
promoting, regulatory T-cells (Tregs) (2). Additionally, TGF-β inhibits natural killer (NK) cells - one of 
the key components of innate anticancer immunity (3). Interestingly and still poorly understood, the 
HRS cells themselves seem to remain unaffected by the tumor-suppressive properties of TGF-β (4). 
Recent studies on diffuse large B-cell lymphoma (DLBCL) revealed a previously unknown tumor-
suppressive signaling axis involving SMAD1 as a downstream messenger of TGF-β (5). SMAD1 
functions as an intracellular signal transducer between extracellular TGF-β and the nucleus, where it 
modulates the transcription of target genes. This signaling cascade was shown to be recurrently 
inactivated in DLBCL, mainly by hypermethylation of five promoter regions surrounding the SMAD1 
transcription start site, which finally generates a significant growth advantage for lymphoma cells (5). 
In the course of these investigations, we noted that SMAD1 was not expressed in HRS cells of 
screened HL cases. This led us to hypothesize that the absence of SMAD1 expression in HRS cells may 
mechanistically be linked to their resistance to the tumor-suppressive effects of TGF-β (4). 
In order to further elucidate this finding, we analyzed 132 well-characterized archival tissue-
microarrayed cases (6), eleven conventional routine lymphadenectomy specimens of patients 
suffering from all classic HL subtypes [77 nodular scleroses (NS); 48 mixed-cellularity (MC); 7 
lymphocyte-rich (LR); 5 lymphocyte depleted; and 6 unclassifiable classic HL] and fourteen routine 
samples of patients suffering from nodular lymphocyte predominant HL (NLPHL) regarding the 
immunohistochemical expression of SMAD1. Importantly, to guarantee retained antigenicity, only 
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cases containing (physiologically) SMAD1 positive endothelia were considered. We found that the all 
NLPHL (14/14 cases; 100%) and the great majority of classic HL (138/143 cases; 97%; Figure 1 A-B) 
displayed SMAD1 negative LP and HRS cells, respectively. Only in five cases, single HRS cells faintly 
stained for SMAD1 (2 NS; 2 MC; and 1 LR classic HL). With respect to non-neoplastic cells, 65/143 
classic HL (45%) showed moderate (15-49% of TIL) up to abundant (≥50% of TIL) amounts of SMAD1 
positive surrounding TIL, thus being potentially susceptible to the suppressive influence of TGF-β 
(Figure 1 A-B); in NLPHL, 11/14 (79%) instances displayed abundant SMAD1 expressing TIL, including 
TIL involved in resetting around LP cells (Suppl. Figure 1). The presence of abundant SMAD1 
expressing TIL did not correlate with disease stage, patients’ age, gender, presence of B-symptoms, 
EBV-association or outcome, while showing significant correlation with the NS subtype (45/77 NS 
cases, i.e. 58%, compared to 20/66 non-NS cases, i.e. 30%, pChi-square=0.025) and with the amount of 
FOXP3-positive Tregs (Rho=0.351, pSpearmann=0.000053), which both, in turn, may directly be linked to 
the effects of TGF-β, promoting sclerosis and a shift towards Treg differentiation (2). In contrast, 
surrounding plasma cells seemed to lack SMAD1 expression, potentially rendering them insensitive 
for the pro-apoptotic and anti-proliferative signals of TGF-β (7). With regard to plasma cells, this 
largely fits to the newly described negative prognostic impact of their increased numbers in classic HL 
(8). 
To further strengthen our hypothesis, the promoter methylation status of the SMAD1 gene was 
investigated in six different HL cell lines, including one NLPHL cell line (DEV) exactly as described (5). 
Methylation analysis by bisulfite sequencing was successful for three regions of the SMAD1 promoter 
and yielded four hypermethylated cell lines (L428, KMH-2, DEV, HDLM-2), which substantially 
differed particularly regarding their methylation of region A4(3) from cell lines showing no evidence 
for promoter hypermethylation (L1236, L540; Figure 2A). Importantly, KMH-2 is known to be SMAD1 
p.ADTP220fs mutant https://portals.broadinstitute.org/ccle/page?cell_line=KMH2_haematopoietic_and_lymphoid_tissue, which 
additionally points towards a potential role of this gene silencing in lymphomagenesis. 
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The impact of the promoter methylation status of SMAD1 on protein expression was further 
addressed by Western blot analysis, comparing one hypermethylated cell line (DEV) with a cell line 
without hypermethylation (L1236). Concordantly, the expression of SMAD1 differed clearly without 
detectable protein in the DEV cell line (Figure 2B). When treated with the DNA methyltransferase 
(DNMT) inhibitor decitabine (DAC), which reverses, among others, the hypermethylation of the 
SMAD1 promoters, the SMAD1-negative cell line DEV immediately died after exposure. As expected, 
the expression of SMAD1 was not affected by treatment in the L1236 cell line that is not 
hypermethylated. 
To obtain further clinical evidence, the promoter methylation status of SMAD1 was assessed on 
three classic HL patient samples. For this purpose, we used our newly developed, flow sorting–
assisted technique for HRS cell enrichment from formalin-fixed and paraffin-embedded tissues 
allowing for targeted genetic analysis of DNA isolated from classic HL tumor cells (9). In this 
collective, not only the A4(3) promoter region of SMAD1, but also the A1(1) region was substantially 
hypermethylated (Figure 2C). Furthermore, SMAD1 promoter hypermethylation was identified in 
sorted tumor-infiltrating plasma cells, fitting to the immunohistochemically noticed lack of SMAD1 in 
plasma cells. 
Although risk-adjusted standard treatment of HL is successful in over 90% of patients, relapses after 
salvage therapy and refractory cases represent oncological challenges and run an unfavorable clinical 
course with limited therapeutic options. In this context, demethylating agents as DAC and azacytidine 
may be of potential therapeutic interest and have already shown promising effects. At clinically 
relevant concentrations, DAC has been documented to inhibit the growth of classic HL cell lines in 
vitro and a single case observation of regressing relapsed classic HL as an unexpected “side effect” of 
azacytidine has been reported in a patient suffering from concomitant myelodysplastic syndrome 
(10, 11). DAC and azacytidine inhibit DNMTs, and therewith reverse promoter hypermethylation of 
SMAD1 (12). Importantly, promising results with DAC were obtained in DLBCL cell lines lacking 
SMAD1 expression due to promoter hypermethylation too (5). Only four days of treatment were 
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sufficient to restore SMAD1 transcription and protein expression in a subset of initially SMAD1 
negative DLBCL cell lines, which was corroborated by observations in a patient-derived xenograft 
DLBCL mouse model with proven SMAD1 promoter hypermethylation (5). Analogous to this, we 
treated the SMAD1-negative HL cell line DEV with DAC. Indeed, immediately after exposure, the cells 
died, possibly due to marked responsiveness towards DAC. 
Since therapeutic reversion of SMAD1 promoter hypermethylation would be of potential relevance 
only in the presence of TGF-β receptors (TGFBR), we analyzed publically available [Gene Expression 
Omnibus (GEO) accession no. GSE12453] and own (GEO accession no. GSE147387) gene expression 
data of primary HRS and LP cells and cell lines to estimate whether HRS and LP cells express TGFBR 
and associated proteins (ACVR1, ACVR1B, ACVR1C, ACVR2A, ACVR2B, ACVRL1, AMHR2, BMPR2, 
TGFBR1, TGFBR2, TGFBR3, TGFBRAP1). The classic HL cell line KMH-2 contained relevant transcript 
levels of all TGFBR types, HDLM-2 expressed TGFBR1 and TGFBR3, and the NLPHL cell line DEV – 
TGFBR1; the classic HL cell lines L1236 and L428 exhibited TGBRAP1 transcripts. 
In summary, our data suggest a likely important, not yet described role of SMAD1 hypermethylation 
in HL potentially causing an imbalance of the TGF-β signaling axis responses in involved tissues. 
SMAD1 has been demonstrated to be part of the TGF-β-mediated anti-proliferative pathway in 
different B-cell lymphomas. Intriguingly, lymphomas with mutated or knocked-out SMAD1 were 
protected from the tumor-suppressive effects of TGF-β (13). 
Lack of SMAD1 expression in HRS and LP cells due to promoter hypermethylation or gene mutation 
may analogously contribute to their resistance towards the pro-apoptotic and anti-proliferative 
effects of TGF-β, despite the presence of TGFBR transcripts. This hypothesis is further supported by 
observations in EBV-positive classic HL, in which decreased SMAD2 levels due to EBNA1-mediated 
increased protein turnover (14) disable TGF-β signaling, being congruent to our data regarding 
SMAD1 downregulation in HRS cells. 
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In contrast, retained SMAD1 expression in surrounding TIL may be contributive to immune escape, as 
intact TGF-β signaling promotes T-cell differentiation into tumor-supporting Tregs (2), which is 
reflected by the observed correlation between higher amounts of FOXP3 positive Tregs and 
expression of SMAD1 in TIL. The connection between the tumor-suppressive effects of TGF-β on TIL 
has recently been a subject of a promising clinical study in which the infusion of TGF-β insensitive T-
cells was successfully used in patients with EBV-positive relapsed classic HL (15). 
Our data suggest a possible rationale for the application of a more tailored treatment with 
hypomethylating agents in HL that may be worth of prospective investigations, as respective agents 
such as DAC already showed promising results in SMAD1 hypermethylated DLBCL (5) and in classic HL 
cell lines (10). 
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Figure 1: Expression of SMAD1 in classic Hodgkin lymphoma (cHL) 
A: Tissue microarrayed archival mixed cellularity cHL with moderate amounts of SMAD1 positive 
tumor-infiltrating lymphocytes (TIL) and a few strongly staining endothelia. Note that all Hodgkin and 
Reed-Sternberg (HRS) cells are negative. B: Diagnostic lymphadenectomy of a nodular sclerosis cHL 
with abundant SMAD1 positive TIL and a few strongly staining endothelia. Note that all HRS cells are 
negative. Immunoperoxidase staining, magnification 400x. 
 
Figure 2: The SMAD1 promoter region is hypermethylated in Hodgkin lymphoma (HL) cell lines and 
patient samples. 
A: Methylation analysis by bisulfite sequencing of region A1(1), A4(3) and B2(5) within the SMAD1 
promoter in a panel of HL cell lines. Each circle represents one CG dinucleotide; black circles indicate 
methylated, white circles indicate unmethylated cytosines. Each line represents one clone, 2-3 clones 
were sequenced per sample. X indicates aligned mismatches between genomic and bisulfite 
sequences. The cell line KMH-2 has a known frame-shift mutation at the SMAD1 locus B: SMAD1 
expression at the protein level after 0 (-) or 1 (+) μM decitabine (DAC) treatment for 96 hours of two 
HL cell lines as determined by Western blotting. Results from two independent experiments are 
exemplified. DAC-treated samples of the DEV cell line are not shown due to lack of protein after 
demethylating treatment. C: Methylation analysis by bisulfite sequencing of region A1(1), A4(3) and 
B2(5) within the SMAD1 promoter in three classic HL patient samples. Each circle represents one CG 
dinucleotide; black circles indicate methylated, white circles indicate unmethylated cytosines. Each 
line represents one clone, 2-3 clones were sequenced per sample. X indicates aligned mismatches 





Suppl. Figure 1: Expression of SMAD1 in nodular lymphocyte predominant (LP) Hodgkin lymphoma  
Substantial amounts of SMAD1 positive tumor-infiltrating lymphocytes including such that rim the 
neoplastic LP cell. Note that the large LP cells, including the rimmed one, are negative. 
Immunoperoxidase staining, magnification 400x. 
